The search result changed since you submitted your search request. Documents might be displayed in a different sort order.
  • search hit 1 of 6
Back to Result List

Week one FLT-PET response predicts complete remission to R-CHOP and survival in DLBCL

Please always quote using this URN: urn:nbn:de:bvb:20-opus-120659
  • Despite improved survival in the Rituximab (R) era, a considerable number of patients with diffuse large B-cell lymphoma (DLBCL) ultimately die from the disease. Functional imaging using [18F]fluorodeoxyglucose-PET is suggested for assessment of residual viable tumor very early during treatment but is compromised by non-specific tracer retention in inflammatory lesions. The PET tracer [18F]fluorodeoxythymidine (FLT) as surrogate marker of tumor proliferation may overcome this limitation. We present results of a prospective clinical studyDespite improved survival in the Rituximab (R) era, a considerable number of patients with diffuse large B-cell lymphoma (DLBCL) ultimately die from the disease. Functional imaging using [18F]fluorodeoxyglucose-PET is suggested for assessment of residual viable tumor very early during treatment but is compromised by non-specific tracer retention in inflammatory lesions. The PET tracer [18F]fluorodeoxythymidine (FLT) as surrogate marker of tumor proliferation may overcome this limitation. We present results of a prospective clinical study testing FLT-PET as superior and early predictor of response to chemotherapy and outcome in DLBCL. 54 patients underwent FLT-PET prior to and one week after the start of R-CHOP chemotherapy. Repetitive FLT-PET imaging was readily implemented into the diagnostic work-up. Our data demonstrate that the reduction of FLT standard uptake valuemean (SUVmean) and SUVmax one week after chemotherapy was significantly higher in patients achieving complete response (CR, n=48; non-CR, n=6; p<0.006). Martingale-residual and Cox proportional hazard analyses showed a significant monotonous decrease of mortality risk with increasing change in SUV. Consistent with these results, early FLT-PET response showed relevant discriminative ability in predicting CR. In conclusion, very early FLT-PET in the course of R-CHOP chemotherapy is feasible and enables identification of patients at risk for treatment failure.show moreshow less

Download full text files

Export metadata

Additional Services

Share in Twitter Search Google Scholar Statistics
Metadaten
Author: Ken Herrmann, Andreas K. Buck, Tibor Schuster, Kathrin Abbrederis, Christina Blümel, Ivan Santi, Martina Rudelius, Hans-Jürgen Wester, Christian Peschel, Markus Schwaiger, Tobias Dechow, Ulrich Keller
URN:urn:nbn:de:bvb:20-opus-120659
Document Type:Journal article
Faculties:Medizinische Fakultät / Klinik und Poliklinik für Nuklearmedizin
Medizinische Fakultät / Pathologisches Institut
Language:English
Parent Title (English):Oncotarget
ISSN:1949-2553
Year of Completion:2014
Volume:5
Issue:12
Pagenumber:4050-59
Source:Oncotarget, Vol. 5, No. 12, 4050-59
Dewey Decimal Classification:6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit
Tag:DLBCL; FLT-PET; [18F]Fluorodeoxythymidine; lymphoma; positron emission tomography
Release Date:2016/02/12
Licence (German):License LogoCC BY: Creative-Commons-Lizenz: Namensnennung